Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


MANAGEMENT

Executive Officers and Directors

        Our current executive officers, directors and key employees, and their ages and positions as of June 30, 2014, are as set forth below:

Name
  Age   Position

Executive Officers

         

Jeffrey S. Hatfield

    56   President, Chief Executive Officer and Director

Richard Gregg, M.D. 

    65   Chief Scientific Officer

Richard Morris(1)

    41   Chief Financial Officer

Arthur Fratamico, R.Ph.(1)

    48   Chief Business Officer

Directors

   
 
 

 

Peter Barrett, Ph.D. 

    61   Director

Robert V. Gunderson, Jr. 

    62   Director

Donald Hayden, Jr. 

    58   Chairman of the Board and Director

Charles W. Newhall, III

    69   Director

Bryan Roberts, Ph.D. 

    47   Director

(1)
Commenced employment in May 2014.

        Jeffrey S. Hatfield has served as President, Chief Executive Officer and a member of our board of directors since March 2004. Prior to joining Vitae, Mr. Hatfield worked at Bristol-Myers Squibb, a large publicly-traded biopharmaceutical company, which he joined in 1985, in a variety of executive positions, including: Senior Vice President of Bristol-Myers Squibb's Virology and Immunology Divisions from 2000 to 2004; President and General Manager, Canada from 1997 to 2000; and Vice President, U.S. Managed Health Care from 1996 to 1997. In 2014, Mr. Hatfield became a director of Ambit Biosciences, a biopharmaceutical company. Mr. Hatfield received a Masters in Business Administration from The Wharton School, University of Pennsylvania and received a bachelor's degree in Pharmacy from Purdue University. Our board of directors believes that Mr. Hatfield's position as our Chief Executive Officer, his extensive experience in general management and his experience in the biopharmaceutical industry qualify him to serve as a member of our board of directors.

        Richard Gregg, M.D. has served as our Chief Scientific Officer since 2008. Prior to joining Vitae, Dr. Gregg worked at Bristol-Myers Squibb, which he joined in 1988, in a variety of positions, including Vice President of Clinical Discovery from 2001 to 2007 and Vice President of Metabolic and Cardiovascular Drug Discovery from 1999 to 2001. Dr. Gregg's career in the industry was preceded by 10 years of studying disorders of lipid and lipoprotein metabolism at the National Heart, Lung and Blood Institute. Dr. Gregg received a Medical Doctorate from Stanford School of Medicine and received a Masters of Science and a bachelor's degree in Biochemistry from Iowa State University.

        Richard Morris has served as our Chief Financial Officer since May 2014. Prior to joining us, Mr. Morris worked at ViroPharma Incorporated, which he joined in 2001, in a variety of positions, including Vice President, Financial Planning and Strategic Analysis from 2012 to 2014, Vice President, Chief Accounting Officer from 2011 to 2014, Controller and Chief Accounting Officer from 2008 April 2011 and Controller from 2005 through 2008. Prior to joining ViroPharma, Mr. Morris worked for KPMG LLP in their Healthcare Assurance practice. Mr. Morris received a bachelor's degree in Accounting from Saint Joseph's University and has been a CPA since 1999.

        Arthur Fratamico, R.Ph. has served as our Chief Business Officer since May 2014. Prior to joining us, Mr. Fratamico served as chief business officer of Flexion Therapeutics, Inc. from June 2012 through 2014. Prior to Flexion, Mr. Fratamico led the business development efforts, including overseeing numerous

119